(BO25126)A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with Operabl...

PrintE-mail
Title (BO25126)A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Primary Breast Cancer
Contact CU
Principal Investigator Ellis Levine, MD
Study Number 203811
Phase1
Summary To compare invasive disease-free survival (IDFS) in patients with HER2-positive breast cancer randomized to chemotherapy plus one year of trastuzumab plus placebo or chemotherapy plus one year of trastuzumab plus pertuzumab.
Eligibility Please see Clinicaltrials.gov link for the eligibility criteria.
For more information about the clinical study go to Clinicaltrial.Gov